Why ClearPoint Neuro, Inc.’s (CLPT) Stock Is Down 5.30%
As of Tuesday, October 06, ClearPoint Neuro, Inc.’s CLPT share price has dipped by 5.30%, which has investors questioning if this is right time to buy.Rosalio Madrigal
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Rosalio Madrigal
Cynthia McLaughlin
Rosalio Madrigal
Michael Rose
Tudor Pop
| Share Statistics | CLPT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $351.4 | $408.1 | 34% |
|
| Shares Out (Mil) | 30.2 | 40.7 | 37% |
|
| Institutional Ownership | 87.9% | 82.6% | 55% |
|
| Float (Mil) | 26.3 | 35.1 | 33% |
|
| Beta | 1.27 | 0.86 | 74% |
|
| Avg Daily Volume (000s) | 949 | 288 | 68% |
|
| Price Change (52-week) |
(54.0%) | 64.2% | 16% |
|
| Growth | CLPT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 23.7% | 11.8% | 85% |
|
| Net Income (5yr) | (30.3%) | (5.6%) | 14% |
|
| EPS (5yr) | (16.1%) | 10.2% | 17 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 0.9% | (15.5%) | 65% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.315) | ($1.305) | ($1.195) | |
| Month Ago EPS | ($0.315) | ($1.305) | ($1.195) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 3 | |
| Three Months Ago EPS | ($0.263) | ($1.113) | ($0.940) | |
| Year/Year Chg | (16.2%) | 44.7% | 8.6% | |
| Financials | CLPT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $42 | $141 | 18% |
|
| Net Income (TTM) (Mil) | ($35) | ($9) | 20% |
|
| EPS (TTM) | ($1.182) | ($0.400) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($30) | ($2) | 13% |
|
| Net Cash Flow (TTM) (Mil) | ($11) | $1 | 30% |
|
| Long-Term Debt (Q1) (Mil) | $64 | $26 | 41% |
|
| Enterprise Value (Q1) (Mil) | $457 | $418 | 33% |
|
| Valuation | CLPT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 32.91 | 2.71 | 97% |
|
| P/E | na | 25.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.5 | na |
|
| Ratios | CLPT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 62.6% | 58.7% | 75% |
|
| Net Margin | (81.8%) | (6.9%) | 9% |
|
| ROA | (46.2%) | (12.2%) | 12% |
|
| ROE | (226.5%) | (10.7%) | 4% |
|
| Liabilities to Assets | 87.6% | 47.2% | 82% |
|
| F-Score | 2 | 4 | 7% |
|
ClearPoint Neuro, Inc. did not pass any screens on 10/5/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors